<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274272</url>
  </required_header>
  <id_info>
    <org_study_id>P201404-31</org_study_id>
    <nct_id>NCT02274272</nct_id>
  </id_info>
  <brief_title>Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenMont Biotech Incorporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenMont Biotech Incorporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of probiotics ADR-1/GMNL-263
      capsules (Lactobacillus reuteri ADR-1/ Lactobacillus reuteri GMNL-263) for the treatment of
      adults with type2 DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background：Based on animal studies, intake of probiotic bacteria was suggested to improve
      insulin sensitivity by reducing inflammation.

      Objective ： The objective of this study was to determine the effects of supplementation with
      the probiotic strain Lactobacillus reuteri ADR-1(ADR-1) and Lactobacillus reuteri GMNL-263
      (GMNL-263) over six months on metabolic profiles, intestinal microbiota profiles and
      biomarkers of inflammation in type 2 diabetes patents. Methods ： This randomized double-blind
      placebo-controlled clinical trial was performed on 120 diabetic patients. Subjects were
      divided into 3 groups: 40 subjects in the group A received placebo, 40 subjects in the group
      B received ADR-1 (4 x 109 colony-forming units/d), and 40 subjects in the group C received
      GMNL-263. (2 x 1010 cells/d) for 6 months. Fasting blood samples were taken at baseline and
      after intervention to measure metabolic profiles and biomarkers of inflammation including C
      reactive protein (CRP), Interleukin 6 (IL-6) and Tumor necrosis factor-alpha( TNF-α). The
      intestinal microbiota profiles were detected in stool samples by real-time polymerase chain
      reaction (RT-PCR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood sugar</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting blood samples of 120 diabetic patients will be were taken at baseline and after intervention to measure blood sugar(mg/dL) and HbA1c(%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood fat</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting blood samples of 120 diabetic patients will be were taken at baseline and after intervention to measure cholesterol(mg/dL) ,triglycerides(TG, mg/dl), high density lipoprotein (HDL, mg/dl), low density lipoprotein (LDL, mg/dl).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the DM marker</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting blood samples of 120 diabetic patients will be were taken at baseline and after intervention to measure insulin(μIU/mL), C-peptide(ng/mL), Homeostasis model assessment for insulin resistance (HOMA-IR, ratio)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADR-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus reuteri GMNL-89</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GMNL-263</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus reuteri GMNL-263</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ADR-1</intervention_name>
    <description>two ADR-1 capsules, once daily, QD</description>
    <arm_group_label>ADR-1</arm_group_label>
    <other_name>Lactobacillus reuteri GMNL-89</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GMNL-263</intervention_name>
    <description>two GMNL-263 capsules, once daily, QD</description>
    <arm_group_label>GMNL-263</arm_group_label>
    <other_name>Lactobacillus reuteri GMNL-263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>two placebo capsules, once daily, QD</description>
    <arm_group_label>Placebo Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes with a duration&gt; 6 months

          2. 7 % &lt; HbA1c ≦ 10 %

          3. Adults 25- 70 years of age

          4. BMI&gt;18.5

        Exclusion Criteria:

          1. Pregnancy

          2. Subjects with any other serious diseases such as cancer (patient with benign tumor
             under medical control should not be ruled out), kidney failure / dialysis, heart
             disease, stroke.

          3. Autoimmune Disease

          4. Administration of other healthy food for diabetes 4 weeks before inclusion

          5. Administration of probiotic 4 weeks before inclusion

          6. Administration of antibiotics 4 weeks before inclusion

          7. Participation in other clinical trials

          8. ALT/SGPT or AST/SGOT &gt; 3x upper limit of normal (ULN)

          9. eGFR&lt;30mL/min/1.73m2

         10. Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption
             syndrome, or inability to take oral medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yi shing Chen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GenMont Biothech Incorporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genmont</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lactobacillus reuteri</keyword>
  <keyword>type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

